| Patent Number |
Title Of Patent |
Date Issued |
| RE38459 |
Emulsion stability |
March 9, 2004 |
| An injectable physiologically acceptable aqueous phase fluorocarbon emulsion, which has substantially no free fluorocarbon, has an excellent stability is prepared by a process of the invention. Typically, more than about 99.8 wt. % of the fluorocarbon remains in the size range of about |
| 7414034 |
Treatment of Parkinson's disease with oligonucleotides |
August 19, 2008 |
| The present invention relates to a method of treatment of Parkinson's disease, and to the use of antisense oligonucleotides or triplex oligonucleotides introduced into targeted brain structures to decrease the function of brain circuits known to be overactive in the Parkinsonian brai |
| 7402401 |
Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
July 22, 2008 |
| In vitro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to rea |
| 7345020 |
Mimetics of CD4 that inhibit immune response |
March 18, 2008 |
| The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4.sup.+ T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering |
| 7316902 |
Compositions that specifically bind to colorectal cancer cells and methods of using the same |
January 8, 2008 |
| A unique transcription product, CRCA-1, and alternative translation products generated therefrom, are disclosed. The transcript and its translation products are markers for colorectal cells. Screening and diagnostic reagents, kits and methods for metastasized colorectal cancer are di |
| 7297330 |
Low dose haptenized tumor cell and tumor cell extract immunotherapy |
November 20, 2007 |
| This invention relates to compositions comprising haptenized tumor cells and extracts thereof, methods for preparing the compositions, vaccines comprising such haptenized tumor cells, and methods for treating cancer with such vaccines. In a specific embodiment, melanoma cells are hap |
| 7278420 |
Oropharyngeal airway |
October 9, 2007 |
| An oropharyngeal device for insertion into the mouth of a patient. The device includes a body having a distal end and a proximal end with a flange formed at the proximal end. The distal end is inserted into the mouth until the flange is disposed outside and adjacent to the patient's |
| 7259140 |
Heparin-binding peptides and uses thereof |
August 21, 2007 |
| Heparin-binding peptides are provided of the formula R.sub.1(X.sub.1B.sub.1B.sub.2X.sub.2B.sub.3X.sub.3Y.sub.1R.sub.2)R.sub.nR- .sub.3, R.sub.1(X.sub.1B.sub.1B.sub.2B.sub.3X.sub.2X.sub.3B.sub.4X.sub.4Y.- sub.1R.sub.2)R.sub.nR.sub.3, and C(X.sub.1B.sub.1B.sub.2B.sub.3X.sub.2X.sub.3B.sub |
| 7226741 |
Multimerization of HIV-1 Vif protein as a therapeutic target |
June 5, 2007 |
| One approach to treating individuals infected with HIV-1 is to administer to such individuals compounds that directly interfere with and intervene in the machinery by which HIV-1 replicates itself within human cells. Although the specific role of HIV-1 viral protein Vif in the viral life |
| 7223584 |
Recombinant rabies vaccine and methods of preparation and use |
May 29, 2007 |
| Live rabies virus vaccines comprising a recombinant rabies virus genome which overexpresses the rabies virus G protein increase apoptotic activity in infected cells, and enhance the generation of anti-rabies immunity in a subject. |
| 7220834 |
FHIT proteins and nucleic acids and methods based thereon |
May 22, 2007 |
| The present invention relates to nucleotide sequences of FHIT genes and amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof, and antibodies thereto. The FHIT gene sequence is mutated in diseases involving cell overproliferation, particularly mal |
| 7195910 |
Human tyrosine hydroxylase promoter and uses thereof |
March 27, 2007 |
| The present invention provides an isolated, purified and characterized human tyrosine hydroxylase (hTH) promoter nucleic acid sequence. The invention further provides a method of selecting TH positive (TH+) cells by preparing a construct comprising a hTH promoter operably linked to a |
| 7175995 |
TCL-1 protein and related methods |
February 13, 2007 |
| The present invention relates to nucleotide sequences of TCL-1 genes and amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof, and antibodies thereto. The TCL-1 gene sequence is preferentially expressed early in T and B lymphocyte differentiation. Th |
| 7160913 |
Methods and kit for treating Parkinson's disease |
January 9, 2007 |
| The efficacy of levodopa therapy in patients being treated for Parkinson's disease is enhanced by administering high doses of a partial glycine agonist. The frequency and severity of levodopa-induced side effects in Parkinson's disease patients are also reduced by administration of a |
| 7141417 |
Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene |
November 28, 2006 |
| The invention relates to isolated polynucleotides homologous with a portion of one strand of the human tumor suppressor gene, FEZ1, and to the tumor suppressor protein encoded thereby, Fez1. The polynucleotides are useful, for example, as probes, primers, portions of expression vecto |
| 7135333 |
Compositions that specifically bind to colorectal cancer cells and methods of using the same |
November 14, 2006 |
| A unique transcription product, CRCA-1, and alternative translation products generated therefrom, are disclosed. The transcript and its translation products are markers for colorectal cells. Screening and diagnostic reagents, kits and methods for metastasized colorectal cancer are di |
| 7097839 |
ST receptor binding compounds and methods of using the same |
August 29, 2006 |
| Conjugated compounds which comprises an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent, and a conjugated compound which comprises an ST receptor binding moiety and a rad |
| 7074413 |
Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife |
July 11, 2006 |
| Live, attenuated recombinant rabies virus vaccines are generated using reverse genetics to combine the antigenic determinants that render the rabies virus non-pathogenic with the determinants that are responsible for the elicitation of an effective anti-rabies immune response. These |
| 7071319 |
Recombinant antibodies, and compositions and methods for making and using the same |
July 4, 2006 |
| Recombinant antibodies are disclosed. The nucleic acid and encoded amino acid sequences of the heavy and light chain immunoglobulins of human monoclonal rabies virus neutralizing antibodies, and their use, are described. |
| 6974571 |
Isolated stromal cells and methods of using the same |
December 13, 2005 |
| Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous |
| 6942985 |
Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
September 13, 2005 |
| In vitro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to rea |
| 6924414 |
Muir-torre-like syndrome in Fhit deficient mice |
August 2, 2005 |
| The invention provides nonhuman transgenic animals with a disrupted FHIT gene. The invention further provides transgenic mice in which one or both Fhit alleles have been inactivated. Preferably, the Fhit-deficient mice develop multiple tumors of both visceral and sebaceous origin, simila |
| 6897296 |
Antibody that specifically binds an Mch5 polypeptide |
May 24, 2005 |
| The invention provides an isolated gene encoding Mch4 or an isolated gene encoding Mch5 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch4 or Mch5 or functional fragment thereof. The gene or nucleic acid sequences can be single or |
| 6890532 |
Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related met |
May 10, 2005 |
| Human monoclonal rabies virus neutralizing antibodies represent a safe and efficacious post-exposure prophylactic therapy for individuals exposed to a rabies virus. The nucleic acid and encoded amino acid sequences of the heavy and light chain immunoglobulins of human monoclonal rabies v |
| 6855801 |
Peptides modulating activities of heparin other glycosaminoglycans or proteoglycans |
February 15, 2005 |
| The present invention involves peptides of various sequences and sizes and methods of using said peptides with a strong affinity for glycosaminoglycans and proteoglycans, wherein said peptides interact strongly with heparin, other glycosaminoglycans, or proteoglycans (PGs). |
| 6855308 |
PACAP compositions and methods for tumor imaging and therapy |
February 15, 2005 |
| Tumors expressing VPAC receptors can be imaged or treated with compounds comprising PACAP, or a biologically active PACAP fragment or analog. |
| 6844421 |
CD4-derived peptides that inhibit immune response |
January 18, 2005 |
| The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4.sup.+ T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering suc |
| 6844153 |
Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
January 18, 2005 |
| Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing metastatic colorectal cancer or primary and/or metastatic sto |
| 6824759 |
Radiolabeled vasoactive intestinal peptide analogs for imaging and therapy |
November 30, 2004 |
| This invention relates to a radiodiagnostic agent to image tumors. A composition for a tumor imaging agent, a method and kit for preparing a tumor imaging agent, and a radiolabeling reagent for preparing the tumor imaging agent are provided. Methods of using the tumor imaging agent to |
| 6822080 |
Human cyclin-dependent kinase-like proteins and methods of using the same |
November 23, 2004 |
| Substantially pure human cyclin-dependent kinase-like proteins PITALRE and PISSLRE and isolated protein complexes that comprise PITALRE or PISSLRE are disclosed. Isolated nucleic acid molecule that encode PITALRE or PISSLRE, or a fragment thereof; recombinant expression vectors that |
| 6821947 |
Endorepellin: methods and compositions for inhibiting angiogenesis |
November 23, 2004 |
| Angiogenesis is a highly regulated process, yet many diseases are driven by unregulated angiogenesis. For example, the growth and metastasis of tumors is dependent on the growth of new blood vessels, which nurture the tumor by providing not only a growth-conducive environment but also a |
| 6797812 |
Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use |
September 28, 2004 |
| The invention relates to an isolated nucleic acid molecule encoding a caspase-14 polypeptide or functional fragment thereof, a vector that contains the nucleic acid molecule and a host cell that contains the vector. The invention also relates to an isolated gene encoding caspase-14, |
| 6797728 |
Use of intracellular calcium chelators to increase surfactant secretion in the lungs |
September 28, 2004 |
| Pulmonary surfactant is required in order to reduce surface tension in the lungs so that less effort is needed to reinflate the lungs after exhalation. A number of diseases and conditions exist that disrupt the normal flow of surfactant secretion, resulting in respiratory distress or |
| 6780409 |
Glutamic acid decarboxylase (GAD) based delivery system |
August 24, 2004 |
| The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an a |
| 6774217 |
FHIT proteins and nucleic acids and methods based thereon |
August 10, 2004 |
| The present invention relates to nucleotide sequences of FHIT genes and amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof, and antibodies thereto. The FHIT gene sequence is mutated in diseases involving cell overproliferation, particularly maligna |
| 6767704 |
Methods of screening and diagnosing esophageal cancer by determining guanylin cyclase C expressi |
July 27, 2004 |
| Screening and diagnostic reagents, kits and methods for primary and/or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of fo |
| 6730779 |
Antibody that specifically binds an Mch4 polypeptide |
May 4, 2004 |
| The invention provides an isolated gene encoding Mch4 or an isolated gene encoding Mch5 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch4 or Mch5 or functional fragment thereof. The gene or nucleic acid sequences can be single or |
| 6716960 |
Mch3, a novel apoptotic protease, nucleic acids encoding and methods of use |
April 6, 2004 |
| The invention provides an isolated gene encoding Mch3, or functional fragment thereof. Also provided is an isolated nucleic acid sequence encoding Mch3 or functional fragment thereof. The gene or nucleic acid sequence can be single or double stranded nucleic acids corresponding to co |
| 6713280 |
Enhancement of peptide cellular uptake |
March 30, 2004 |
| Peptide conjugates of the formula are providedwherein: n is from 1 to 10; X is (a) C.dbd.O, when the R--X group is attached to: (i) the N-terminus of the peptide, or (ii) a side chain of the peptide where the functional group of the side chain to which the R--X group is attached i |
| 6686459 |
Mch3, a novel apoptotic protease, nucleic acids encoding and methods of use |
February 3, 2004 |
| The invention provides an isolated gene encoding Mch3, or functional fragment thereof. Also provided is an isolated nucleic acid sequence encoding Mch3 or functional fragment thereof. The gene or nucleic acid sequence can be single or double stranded nucleic acids corresponding to co |
| 6685913 |
Lipid soluble radioactive metal chelates for tumor therapy |
February 3, 2004 |
| The present invention is a method of injecting a class of lipid soluble radioactive metal chelate compounds for intratumoral treatment of malignant, benign, metastatic, or inoperable tumors. |
| 6663856 |
Method of inhibiting cancer cell growth using a vector expressing pRb2/P130 |
December 16, 2003 |
| Methods of inhibiting growth of cancer cells and treating cancer in a patient by administration of a vector expressing pRb2/p130 are provided. |
| 6660906 |
Tpl2 transgenic knockout mice |
December 9, 2003 |
| The present invention is directed to animal having functionally disrupted endogenous Tpl2. These animals are resistant to Lps induced endotoxin shock and TNF.alpha.-mentioned inflammatory disease. A method of identifying Tpl2 specific inhibitors of endotoxin shock or antagonists to i |
| 6653443 |
Multimerization of HIV-1 Vif protein as a therapeutic target |
November 25, 2003 |
| One approach to treating individuals infected with HIV-1 is to administer to such individuals compounds that directly interfere with and intervene in the machinery by which HIV-1 replicates itself within human cells. Although the specific role of HIV-1 viral protein Vif in the viral life |
| 6617427 |
Nucleic acid molecule encoding an ankyrin repeat TVL-1 protein and methods of use thereof |
September 9, 2003 |
| Nucleic acid molecules, proteins and antibodies are provided which may be used in biological screens to identify therapeutic agents involved in the regulation of cell cycle progression and apoptotic cell death. |
| 6613742 |
Chemokine-derived synthetic peptides |
September 2, 2003 |
| Synthetic peptide analogs of chemokines are designed to include the N- and C-terminal portions of the corresponding naturally occurring chemokine. In particular, synthetic peptide analogs of stromal cell-derived factor-1 (SDF-1) are effective in inhibiting HIV-1 entry and infection via t |
| 6613322 |
Method for treating a subject suffering from conditions associated with an extracellular zinc sp |
September 2, 2003 |
| The present invention provides for a method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase activity which comprises administering to the subject an amount of a zinc sphingomyelinase inhibitor effective to decrease extracellula |
| 6610541 |
Recombinant, active caspases and uses thereof |
August 26, 2003 |
| Rev-caspases comprising a primary product in which the small subunit is N-terminal to the large subunit are provided. Rev-caspases are used for screening and identifying caspase inhibitors and enhancers. Rev-caspase genes can be delivered to cells for gene therapy. |
| 6602659 |
Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
August 5, 2003 |
| In vitro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to rea |
| 6600024 |
Blk genes, gene products and uses thereof in apoptosis |
July 29, 2003 |
| Genes and gene products of Blk, a pro-apoptotic protein in the Bcl-2 gene family, are provided. Effector molecules that either increase or decrease Blk and thus promote or inhibit apoptosis are described. The Blk genes and proteins and effector molecules may be used to treat diseases tha |
